The effectiveness of ropeginterferon alfa-2b was assessed by looking at how many participants achieved complete hematological response, which meant that participants had a red blood cell volume of less than 45% without a recent phlebotomy, normal white cell counts and platelet counts, a normal spleen size, and no blood clots. Overall, 61% of participants had a complete hematological response. The U.S. Food and Drug Administration (FDA) granted the application for Ropeginterferon_alfa-2b orphan drug designation and granted the approval of Besremi to PharmaEssentia Corporation

References
External links
"Ropeginterferon alfa-2b". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT01193699 for "Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA)" at ClinicalTrials.gov
Clinical trial number NCT02218047 for "AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)" at ClinicalTrials.gov
A syphilid is any of the cutaneous and mucous membrane lesions characteristic of secondary and tertiary syphilis.It appears about 10 weeks after infection. Patient may present with prodromal symptoms such as fever, acratia, myalgia arthralgia, headache, anorexia. Its eruption pattern is macular, papular,  follicular papules, or pustule, symmetrical, generalized and dense, round or oval in shape, and is red copper in color. See also
Id reactions
List of cutaneous conditions


== References ==